I'm unable to provide a summary based on the text you provided, as it primarily consists of error messages and security-related content rather than specific information about Omeros Corporation's technologies. If you have access to more detailed content regarding their technologies, pipeline, or scientific advancements, please share that, and I would be happy to help summarize it accurately.

United States

Omeros is a Seattle-based biopharmaceutical company committed to discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system.

Cancer

Cardiovascular Diseases

Central Nervous System (CNS)

Immune System Diseases

Infectious Diseases

Kidney Diseases

Musculoskeletal Diseases

Omeros Corporation

Eye disease

The two active pharmaceutical ingredients (API) in Omidria, phenylephrine and ketorolac, act to maintain pupil size by preventing intraoperative miosis, and reducing postoperative pain. Phenylephrine is an α1-adrenergic receptor agonist and, in the eye, acts as a mydriatic agent by contracting the radial muscle of the iris. Ketorolac is a nonsteroidal anti-inflammatory that inhibits both cyclooxygenase enzymes (COX-1 and COX-2), resulting in a decrease in tissue concentrations of prostaglandins to reduce pain due to surgical trauma. Ketorolac, by inhibiting prostaglandin synthesis secondary to ocular surgical insult or direct mechanical stimulation of the iris, also prevents surgically induced miosis (<a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/205388s006lbl.pdf">Learn more HERE</a>).&nbsp;

OMIDRIA (phenylephrine and ketorolac intraocular solution) 

Hematopoietic cell transplantation

Narsoplimab is a human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the effector enzyme of the lectin pathway of the complement system. The lectin pathway is one of the principal pathways of complement and is activated primarily by tissue damage and microbial infection. Importantly, inhibition of MASP-2 does not appear to interfere with the classical complement pathway, a critical component of the acquired immune response to infection. This novel, proprietary drug is designed to prevent complement-mediated inflammation and endothelial damage while leaving intact the respective functions of the other pathways of innate immunity (<a href="https://www.omeros.com/narsoplimab/">Learn more HERE</a>).&nbsp;

Narsoplimab (OMS721) (MASP-2 inhibitor, lectin pathway)

Blood disorder

Paroxysmal nocturnal hemoglobinuria

OMS906 is a humanized monoclonal antibody targeting mannan-binding lectin-associated serine protease-3 (MASP-3), the key activator of the alternative pathway of complement. The alternative pathway is involved in a wide range of diseases and disorders, including those targeted by marketed alternative pathway inhibitors or those in development. Unlike these drugs, MASP-3 inhibition does not interfere with the classical complement pathway, a critical component of the acquired immune response to infection.

Zaltenibart/OMS906 [MASP-3 inhibitor Antibody]

Addiction

OMS405 (PPARγ agonist)

C3 Glomerulopathy

Lectin pathway disorder

OMS1029 (MASP-2)

Cocaine use disorder

Levodopa-induced dyskinesia associated with Parkinson’s disease

Movement disorder

OMS527 (PDE7 inhibitor)

IgA nephropathy

Kidney disease

Narsoplimab is a human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the effector enzyme of the lectin pathway of the complement system. The lectin pathway is one of the principal pathways of complement and is activated primarily by tissue damage and microbial infection. Importantly, inhibition of MASP-2 does not appear to interfere with the classical complement pathway, a critical component of the acquired immune response to infection. This novel, proprietary drug is designed to prevent complement-mediated inflammation and endothelial damage while leaving intact the respective functions of the other pathways of innate immunity (<a href="https://www.omeros.com/narsoplimab/" rel="noopener" target="_blank">Learn more HERE</a>).

Omeros Corporation

Company Details